Plain-English translation of NCT07039669 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing a medication called , given as an injection under the skin every two weeks, to see if it can help people with moderate to severe COPD (a serious lung disease that makes breathing difficult). Researchers want to know if this new treatment reduces flare-ups and improves lung function in adults who are already on standard COPD medications but still experiencing problems.
Many people with advanced COPD continue to have painful flare-ups that send them to the hospital, even when they're taking their regular medications. This trial exists to see whether this new treatment can better control those flare-ups and improve quality of life for patients who aren't getting enough relief from current options.
You likely qualify if…
You likely don't qualify if…
You would visit a clinic for up to 6 weeks of screening, then be randomly assigned to receive either the new medication or a placebo injection every two weeks for 52 weeks. You'll have regular clinic visits to check your lung function, monitor how you're doing, and report any side effects. After the 52-week treatment period ends, you'll have 8 weeks of follow-up visits. In total, the study lasts about 66 weeks (roughly 15 months).
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
China